NCT07515521 (EVITE-AMD) is a clinical trial in Age - Related Macular Degeneration (AMD), sponsored by Maximilian Pfau.

Who is sponsoring NCT07515521?

NCT07515521 is sponsored by Maximilian Pfau.

What condition does NCT07515521 study?

NCT07515521 studies Age - Related Macular Degeneration (AMD).

Is NCT07515521 still recruiting?

NCT07515521 is currently recruiting now. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT07515521: EVITE-AMD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enhanced Vision and Imaging Tests for Enabling Treatment Trials in Early and Intermediate AMD

Recruiting now Last updated 7 April 2026

What this trial tests

trial in Age - Related Macular Degeneration (AMD) in 150 participants. Currently enrolling.

Timeline

15 February 2026

Primary endpoint
15 December 2028

15 December 2028

Quick facts

Lead sponsor	Maximilian Pfau
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	150
Start date	15 February 2026
Primary completion	15 December 2028
Estimated completion	15 December 2028
Sites	1 location across Germany

Conditions studied

Age - Related Macular Degeneration (AMD) — all drugs for Age - Related Macular Degeneration (AMD) →

Sponsor

Maximilian Pfau

Who can join

18 and older, any sex, with Age - Related Macular Degeneration (AMD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This monocentric prospective longitudinal observational study will validate fundus-tracked dark adaptometry as an endpoint for future treatment trials in early and intermediate age-related macular degeneration (AMD). The study will characterize normative cone- and rod-mediated dark adaptation parameters in healthy volunteers, assess test-retest reliability, quantify sensitivity to change over time, evaluate diagnostic and prognostic validity against AMD stage and structural progression, and investigate imaging-, biomarker-, and genetics-based determinants of impaired dark adaptation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Age - Related Macular Degeneration (AMD)

Currently open trials in the same condition.

NCT07164378 — International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Cent · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07515521 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maximilian Pfau
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07515521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing